Male Cancer Screening Blood Test Package (CANMA)
CANMA – Male Cancer Screening Blood Test Package
Direct answer: CANMA is a tumour-marker blood test profile designed to screen for early cancer risk markers in men.
The CANMA – Male Cancer Screening Profile is a targeted tumour marker screening panel used to detect abnormal protein markers linked with prostate, liver and gastrointestinal cancers. A tumour marker is a measurable substance in blood that may rise when certain cancers develop. This package is offered by healthcare nt sickcare in Pune, Maharashtra, with Home Collection Facility and Direct Walk-in Facility for local patients.
This profile is commonly advised for preventive health screening, family history of malignancy, or clinical suspicion. It supports early risk assessment before visible symptoms progress. Persistent fatigue can be an early symptom. Male reproductive system malignancy is a related condition screened through this panel.
Tests Covered in CANMA Profile
- Beta HCG – tumour marker associated with testicular and reproductive system cancers.
- AFP – alpha-fetoprotein marker used for liver and germ cell tumour screening.
- CA19.9 – carbohydrate antigen marker linked to gastrointestinal malignancies.
- CEA – carcinoembryonic antigen used in colorectal and digestive tract cancer monitoring.
- PSA – prostate-specific antigen for prostate cancer risk assessment.
- Free PSA – ratio marker improving prostate cancer screening accuracy.
Who should consider this test?
Direct answer: Adult men seeking preventive cancer risk screening or advised by doctors for tumour marker evaluation.
- Men above 40 years for preventive cancer screening
- Family history of prostate or gastrointestinal cancer
- Follow-up monitoring after cancer treatment
Related Resources
Learn more about tumour markers from National Cancer Institute tumour marker guide.
FAQs
This test is recommended for men above 40 years, those with family history of cancer, or when doctors advise tumour marker screening.
It helps identify elevated tumour markers linked to prostate, liver and gastrointestinal cancers for early risk detection.
Fasting is not mandatory, but your doctor may advise specific preparation based on clinical history.
No. It is a screening tool. Abnormal results require further imaging or biopsy for confirmation.
Â
Medical Disclaimer: This CANMA screening profile is for health risk assessment only and does not replace clinical diagnosis. Read full policy at disclaimer policy. Product images used on this page are AI-generated with credits to Google Gemini and Shopify Magic.
Original: $2,499.00
-70%$2,499.00
$749.70Product Information
Product Information
Shipping & Returns
Shipping & Returns
Description
CANMA – Male Cancer Screening Blood Test Package
Direct answer: CANMA is a tumour-marker blood test profile designed to screen for early cancer risk markers in men.
The CANMA – Male Cancer Screening Profile is a targeted tumour marker screening panel used to detect abnormal protein markers linked with prostate, liver and gastrointestinal cancers. A tumour marker is a measurable substance in blood that may rise when certain cancers develop. This package is offered by healthcare nt sickcare in Pune, Maharashtra, with Home Collection Facility and Direct Walk-in Facility for local patients.
This profile is commonly advised for preventive health screening, family history of malignancy, or clinical suspicion. It supports early risk assessment before visible symptoms progress. Persistent fatigue can be an early symptom. Male reproductive system malignancy is a related condition screened through this panel.
Tests Covered in CANMA Profile
- Beta HCG – tumour marker associated with testicular and reproductive system cancers.
- AFP – alpha-fetoprotein marker used for liver and germ cell tumour screening.
- CA19.9 – carbohydrate antigen marker linked to gastrointestinal malignancies.
- CEA – carcinoembryonic antigen used in colorectal and digestive tract cancer monitoring.
- PSA – prostate-specific antigen for prostate cancer risk assessment.
- Free PSA – ratio marker improving prostate cancer screening accuracy.
Who should consider this test?
Direct answer: Adult men seeking preventive cancer risk screening or advised by doctors for tumour marker evaluation.
- Men above 40 years for preventive cancer screening
- Family history of prostate or gastrointestinal cancer
- Follow-up monitoring after cancer treatment
Related Resources
Learn more about tumour markers from National Cancer Institute tumour marker guide.
FAQs
This test is recommended for men above 40 years, those with family history of cancer, or when doctors advise tumour marker screening.
It helps identify elevated tumour markers linked to prostate, liver and gastrointestinal cancers for early risk detection.
Fasting is not mandatory, but your doctor may advise specific preparation based on clinical history.
No. It is a screening tool. Abnormal results require further imaging or biopsy for confirmation.
Â
Medical Disclaimer: This CANMA screening profile is for health risk assessment only and does not replace clinical diagnosis. Read full policy at disclaimer policy. Product images used on this page are AI-generated with credits to Google Gemini and Shopify Magic.
